The effects of lamotrigine on the pharmacokinetics of lithium.
OBJECTIVE
The treatment of bipolar disorder often includes use of multiple drug therapies. Lithium is one of the most commonly used treatments, but has a narrow therapeutic window. Lamotrigine, an established antiepileptic drug, is emerging as a potentially important new therapy in the treatment of bipolar disorder. The objective of this two-treatment crossover study was to determine whether lamotrigine affects lithium pharmacokinetics.


METHODS
Twenty healthy adult men completed the study. Subjects took 2 g lithium gluconate anhydrous every 12 h in the morning and evening for 5 days and in the morning of day 6, with or without 100 mg lamotrigine once daily in the morning for 6 days. Blood and urine samples were collected on day 6 of both treatments to characterize the pharmacokinetics of lithium using noncompartmental methods.


RESULTS
The geometric least-square mean ratio for renal clearance of lithium between the combination treatment and lithium alone treatment was 0.93 (95% confidence interval 0.85-1.02). Both treatments were well tolerated.


CONCLUSIONS
Lamotrigine does not cause significant change in the pharmacokinetics of lithium.
Chen
C
C
Division of Clinical Pharmacology, Glaxo Wellcome Research & Development, Greenford, Middlesex, UK. cc43624@glaxowellcome.co.uk
Veronese
L
L
Yin
Y
Y
D000328:Adult; D018692:Antimanic Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D019540:Area Under Curve; D018592:Cross-Over Studies; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D000077213:Lamotrigine; D008094:Lithium / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D014227:Triazines / Q000009:adverse effects / Q000494:pharmacology*
D018692:Antimanic Agents; D014227:Triazines; D008094:Lithium; D000077213:Lamotrigine